Guangji Pharmaceutical (000952) In-depth Research: Benefiting from VB2 and VB6 Price Increases, Waiting for 2018 Results to Bloom
Comments on Guangji Pharmaceutical (000952) Annual report: the annual report is in line with expectations and looks forward to a brilliant start of 2018Q1
Guangji Pharmaceutical (000952) Annual report comment: vitamin B2 world leader waits for 2018 results to bloom in the spring
Guangji Pharmaceutical (000952) China News comments: performance is expected to improve the new chairman of the board of directors to take office soon or accelerate the reform of state-owned enterprises.
Guangji Pharmaceutical Industry (000952) China News comments: China News performance is flat and operating efficiency has been significantly improved. National reform is on the way.
Comments on the semi-annual report of Guangji Pharmaceutical Co., Ltd. (000952): VB2 continues to be strong, flexible and huge management changes demonstrate the determination to be bigger and stronger.
Guangji Pharmaceutical (000952) Third Quarterly Report Review: Accelerated Performance, State-owned Enterprise Reform Is Worth Looking Forward to
[Guohai Securities] Guangji Pharmaceutical Quarterly Report Review: VB2 is in a boom cycle, performance exceeds expectations, and national reform expectations are strong
Comments on the Quarterly report of Guangji Pharmaceutical Co., Ltd. (000952): VB2 is in a business cycle with higher-than-expected performance and strong national reform expectations.
[Huatai] Guangji Pharmaceutical Industry: vitamin B2 boom, Q3 performance accelerated growth
Guangji Pharmaceutical (000952) Quarterly Report Review: Vitamin B2 Boom Boosts Q3 Performance Growth Accelerates
[Huatai Securities] Guangji Pharmaceutical: Performance accelerated month-on-month, reaffirming the “increase in holdings” rating
Guangji Pharmaceutical (000952) Announcement Comment: Accelerated month-on-month growth in performance reaffirms “increase holdings” rating
Guangji Pharmaceutical (000952) Company Announces Comments: Product Price Increases, Costs Decline, Performance Continues to Improve
[Haitong Securities] Guangji Pharmaceutical Company Announces Comments: Product Prices Increased, Costs Decreased, and Performance Continued Improvement
Guangji Pharmaceutical (000952) First Coverage Report: Vitamin B2 Sentiment Rise, State-owned Enterprise Reform Expectations Expect
Guangji Pharmaceutical (000952) Comment: VB2 Daikin Industrial Park stops production, maintenance, volume control, price increases, VB2 prices are expected to continue to rise, and expectations for national reform are strong
Guangji Pharmaceutical (000952) Comment: Daikin Industrial Park may stop production and overhaul VB2 and ushered in a new round of price increases
[Southwest Securities] Guangji Pharmaceutical: Daikin Industrial Park stops production and maintenance, and VB2 may welcome a new round of price increases
Review of the semi-annual report of Guangji Pharmaceutical (000952): VB2 prices are on an upward trend, and performance is improving quarterly
No Data